SCHEMBL2576240

SCHEMBL2576240

O=Cc1ccc(-c2ccc(C(=O)O)c(O)c2)s1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.50
ACMSD Q8TDX5 1/20 0.50
MAPT P10636 1/20 0.45
PTPN22 Q9Y2R2 3/20 0.45
APP P05067 1/20 0.44
ERN1 O75460 1/20 0.44
PRF1 P14222 1/20 0.44
SNCA P37840 1/20 0.43
CA12 O43570 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
TSHR P16473 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CYP2E1 P05181 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2A6 P11509 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2561768 0.88 PTPN22 (0.56) HNF4AACMSDMAPTPTPN22APP
SCHEMBL2558645 0.84 MAPT (0.44) MAPTPTPN22APPERN1PRF1
SCHEMBL15329957 0.84 TSHR (0.45) MAPTPTPN22APPERN1PRF1
SCHEMBL2561881 0.81 MAPT (0.44) MAPTPTPN22APPERN1PRF1
SCHEMBL15332488 0.81 ALDH1A1 (0.45) MAPTPTPN22APPPRF1ALDH1A1
SCHEMBL2560700 0.80 ERN1 (0.49) MAPTPTPN22APPERN1PRF1
SCHEMBL2561292 0.79 ERN1 (0.42) MAPTPTPN22APPERN1PRF1
SCHEMBL2558974 0.77 ACMSD (0.56) HNF4AACMSDMAPTCA12ALDH1A1
SCHEMBL22147417 0.76 HNF4A (0.50) HNF4AACMSDMAPTERN1SNCA
SCHEMBL2015912 0.76 APP (0.54) MAPTAPPERN1PRF1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
US-20200197418-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION UNIV GRANADA (ES) 2020-06-25 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200197418-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION DOHH, OGDH, EGLN2 HNF4A 4553/4885ACMSD 1084/4885MAPT 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.